Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Sep 24, 2009


Geneva Bioinformatics and Integromics this week announced that GeneBio's Phenyx software platform for mass spec data analysis has been integrated into Integromics' data analysis and management tool, OmicsHub Proteomics.

As a result, Phenyx and OmicsHub Proteomics users will be able to combine results from two different search engines and increase the accuracy of their protein identifications, the companies said in a joint statement.

OmicsHub was developed by ProteoRed, the Spanish National Proteomics Network, and serves as "an end-to-end proteomics data analysis and management system, from pprotein peak detection to generation of final reports," the companies said. Phenyx was developed in collaboration with the Swiss Institute of Bioinformatics and is used for the identification, quantitation, and characterization of proteins and peptides from mass spec data.

Proxeon will preview ProteinCenter v. 3.0 at the Human Proteome Organization annual meeting starting this weekend in Toronto.

New functionalities to the software include the ability "to discover more about underlying biology by grouping proteins and peptides according to their quantitative profiles and finding differences in the hydrophobicity and isoelectric points of peptides across multiple datasets for method optimization," Proxeon said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.